RMC-GI-102: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (H-55406)
Description
Content
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents to be evaluated in patients with RAS-mutated solid tumors with a focus on GI cancers.
This is an open-label platform study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC) or with novel agents, and to define the Recommended Phase 2 Dose and Schedule (RP2DS).
For more information: https://clinicaltrials.gov/study/NCT06445062
Contact
Phone 1: 713–798–2878
IRB: H-55406
Status:
Active
Created:
